Login Register Cart 0
Generic placeholder image

Current Stem Cell Research & Therapy

Editor-in-Chief

ISSN (Print): 1574-888X
ISSN (Online): 2212-3946

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

What will Become of the Taxpayer Investment in Public Cord Blood Stem Cell Banking?

Author(s): David T Harris* and Scott Israel

Volume 14, Issue 4, 2019

Page: [367 - 372] Pages: 6

DOI: 10.2174/1574888X14666190222184155

Price: $65

Abstract

Cord Blood (CB) is a unique and readily available source of hematopoietic stem cells for transplantation. CB also contains other types of stem cells, including endothelial stem cells and mesenchymal stem cells, that may prove useful in non-traditional clinical uses. Genetic and molecular analyses have demonstrated that CB stem cells lie somewhere between mature stem cells like those found in Bone Marrow (BM), and fetal stem cells. After 25 years of clinical experience, CB is now used in the same fashion as BM for all typical malignant and genetic diseases treated by bone marrow transplant. Due to the establishment of CB banks in the US and abroad, more than 35,000 CB transplants have been performed over the past 25 years. An average of 700-800 CB transplants are performed annually. In addition, CB is now used more frequently for regenerative medicine and tissue engineering applications. At first glance, it seems that everything could not be better with the public cord blood banks and the use of their samples in the clinic. However, a recent report by the Rand Corp. reviewed the US national cord blood stem cell banking program and detailed many ongoing problems. However, some details were omitted from the report that would shed some light on the causes of many of the problems. This paper will summarize the status of the public cord blood stem cell banking program in the US, detail the problems associated with the program that could jeopardize its existence and suggest possible solutions to resolve these issues.

Keywords: Cord blood, stem cells, regenerative medicine, tissue engineering, cord blood banks, transplantation.

« Previous
[1]
Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989; 86(10): 3828-32.
[2]
McGuckin C, Forraz N, Baradez MO, et al. Production of stem cells with embryonic characteristics from human umbilical cord blood. Cell Prolif 2005; 38: 245-55.
[3]
McGuckin CP, Forraz N, Allouard Q, Pettengell R. Umbilical cord blood stem cells can expand hematopoietic and neuroglial progenitors in vitro. Exp Cell Res 2004; 295: 350-9.
[4]
Rogers I, Yamanaka N, Bielecki R, et al. Identification and analysis of in vitro cultured CD45-positive cells capable of multi-lineage differentiation. Exp Cell Res 2007; 313: 1839-52.
[5]
Kucia M, Halasa M, Wysoczynski M, et al. Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4+ very small embryonic-like cells purified from human umbilical cord blood-preliminary report. Leukemia 2007; 21: 297-303.
[6]
Harris DT, He X, Badowski M, Nichols JC. Regenerative Medicine of the Eye: A Short Review.Stem Cell Repair & Regeneration,Vol. 3, Levicar N, Habib NA, Dimarakis I, Gordon MY (Ed.s), Imperial College Press, p. 211-225, London, 2008.
[7]
Sunkomat JNE, Goldman S, Harris DT. Cord blood-derived MNCs delivered intracoronary contribute differently to vascularization compared to CD34+ cells in the rat model of acute ischemia. J Mol Cell Cardiol 2007; 42(6)(Suppl. 1): S97.
[8]
He X, Gonzalez V, Tsang A, Thompson J, Tsang T, Harris DT. Differential gene expression profiling of CD34+CD133+ umbilical cord blood hematopoietic stem-progenitor cells. Stem Cells Dev 2005; 14(2): 188-98.
[9]
Harris D, Schumacher MJ, LoCacsio J, et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc Natl Acad Sci USA 1992; 89: 10006-10.
[10]
Harris DT, Schumacher MJ, Rychlik S, et al. Collection separation and cryopreservation of umbilical cord blood for use in transplantation. Bone Marrow Transplant 1994; 13: 135-43.
[11]
Harris D, LoCascio J, Besencon F. Analysis of the alloreactive capacity of human umbilical cord blood: Implications for graft-versus-host disease. Bone Marrow Transplant 1994; 14: 545-53.
[12]
Harris DT. In vitro and in vivo assessment of the graft-versus-leukemia activity of cord blood. Bone Marrow Transplant 1995; 15: 17-23.
[13]
Harris DT, Schumacher MJ, LoCascio L, Booth A, Bard J, Boyse EA. Immunoreactivity of umbilical cord blood and post-partum peripheral blood with regard to HLA-haploidentical transplantation. Bone Marrow Transplant 1994; 14: 63-8.
[14]
Harris DT. GVL and GVHD Implications of Cord Blood. Proceedings of the international conference/workshop on cord blood transplantation and biology/immunology. Blood Cells 1994; 20: 560-5.
[15]
Harris DT. Experience in autologous and allogeneic cord blood banking. J Hematother 1996; 5(2): 123-8.
[16]
Gluckman E, Broxmeyer HE, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989; 321(17): 1174-8.
[17]
Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored placental blood for unrelated bone marrow reconstitution. Blood 1993; 81: 1679-90.
[18]
Ballen K. Umbilical cord blood transplantation: Challenges and future directions. Stem Cells Transl Med 2017; 6: 1312-5.
[19]
West E. Regenerative Medicine: The Need for a National Strategy. Pharm Technol 2011; 35(7)http://www.pharmtech. com/regenerative-medicine-need-national-strategy
[20]
Kapinos KA, Briscombe B, Gračner T, et al. Challenges to the sustainability of the US public cord blood system. Rand Corporation 2017. ISBN: 978-1-9774-0000-0
[21]
Lee S, Huh JY, Turner DM, et al. Repurposing the cord blood bank for haplobanking of HLA-homozygous iPSCs and their usefulness to multiple populations. Stem Cells 2018; 36(10): 1552-66.
[22]
Laskowitz DT, Bennett ER, Durham RJ, et al. Allogeneic umbilical cord blood infusion for adults with ischemic stroke: Clinical outcomes from a phase I safety study. Stem Cells Transl Med 2018; 7: 521-9.
[23]
You HJ, Namgoong S, Han SK, Jeong SH, Dhong ES, Kim WK. Wound-healing potential of human umbilical cord blood-derived mesenchymal stromal cells in vitro-a pilot study. Cytotherapy 2015; 17(11): 1506-13.
[24]
Park YB, Song M, Lee CH, Kim JA, Ha CW. Cartilage repair by human umbilical cord blood-derived mesenchymal stem cells with different hydrogels in a rat model. J Orthop Res 2015; 33(11): 1580-6.

Rights & Permissions Print Cite
Article Metrics
55
8
© 2024 Bentham Science Publishers | Privacy Policy